|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM143160206 |
| 003 |
DE-627 |
| 005 |
20250205031851.0 |
| 007 |
tu |
| 008 |
231223s2003 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed25n0477.xml
|
| 035 |
|
|
|a (DE-627)NLM143160206
|
| 035 |
|
|
|a (NLM)14597212
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Stewart, Donn M
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a B lymphocytes from individuals with common variable immunodeficiency respond to B lymphocyte stimulator (BLyS protein) in vitro
|
| 264 |
|
1 |
|c 2003
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 11.12.2003
|
| 500 |
|
|
|a Date Revised 08.11.2019
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a B lymphocyte stimulator (BLyS protein) is a member of the human TNF family of ligands. BLyS induces B-lymphocyte proliferation and Ig secretion in vitro and in vivo. These qualities suggest that it may be useful as a therapeutic in the treatment of immunodeficiencies characterized by low or absent serum immunoglobulin, such as common variable immunodeficiency (CVID). CVID is characterized by the inability to generate adequate serum Ig despite normal or slightly depressed peripheral B, T, and myeloid cell populations. We tested the ability of BLyS to stimulate B lymphocytes obtained from CVID patients. Among five patients studied, 60% (three of five) produced normal quantities of IgM when cultured in the presence of BLyS. B-cell proliferation among patients was comparable, with 60% (three of five) responding to BLyS stimulation. These results suggest that BLyS induces proliferative and Ig-secretory responses in B lymphocytes isolated from some CVID patients and lend support to its potential use in therapy of this disorder
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Adjuvants, Immunologic
|2 NLM
|
| 650 |
|
7 |
|a B-Cell Activating Factor
|2 NLM
|
| 650 |
|
7 |
|a B-Cell Activation Factor Receptor
|2 NLM
|
| 650 |
|
7 |
|a BLyS receptor
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin Isotypes
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulins
|2 NLM
|
| 650 |
|
7 |
|a Membrane Proteins
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Tumor Necrosis Factor
|2 NLM
|
| 650 |
|
7 |
|a Recombinant Proteins
|2 NLM
|
| 650 |
|
7 |
|a TNFRSF13C protein, human
|2 NLM
|
| 650 |
|
7 |
|a TNFSF13B protein, human
|2 NLM
|
| 650 |
|
7 |
|a Tumor Necrosis Factor-alpha
|2 NLM
|
| 700 |
1 |
|
|a McAvoy, Michael J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hilbert, David M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nelson, David L
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 109(2003), 2 vom: 15. Nov., Seite 137-43
|w (DE-627)NLM098196855
|x 1521-6616
|7 nnns
|
| 773 |
1 |
8 |
|g volume:109
|g year:2003
|g number:2
|g day:15
|g month:11
|g pages:137-43
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 109
|j 2003
|e 2
|b 15
|c 11
|h 137-43
|